



European ME Alliance, Sønder Alle 5, st 3, 9500 Hobro, Denmark

Email: [info@euro-me.org](mailto:info@euro-me.org)

web: [www.euro-me.org](http://www.euro-me.org)

### **Den juridiske og medicinske situation for patienter med ME (Myalgisk Encefalomyelitis) og CFS (Kronisk Udmattelsessyndrom)**

Myalgisk Encefalomyelitis (ME), blev anerkendt af WHO som en neurologisk sygdom i 1969.

I nogle lande omtales ME som Kronisk Udmattelsessyndrom (CFS). I 1993 blev CFS indsæt som en tilføjelse til ICD-10, men den "træthedsbaserede" definition af CFS fortsætter at skabe forvirring og problemer for patienterne, som Androulla VASSILIOU, tidligere Europæisk sundhedskommissær, har udtalt.

ME kan forekomme i udbrud; én af dem blev for første gang beskrevet i 1934. Ekspert er har placeret ME i samme kategori som kræft og AIDS i slutfasen med hensyn til livskvalitet og grad af lidelse.

#### **Derfor beder vi om følgende:**

- at respektere WHO ICD-10-koden G93.3 for ME som en neurologisk sygdom og sikre, at medlemslandene implementerer dette i deres sundhedssystem;
- at respektere ME-patienternes rettigheder – inkluderet børn – i alle medlemslande;
- at anbefale "The Canadian Consensus Criteria" og "International Consensus Criteria" (sidstnævnte under udarbejdelse) som diagnosekriterier for ME;
- at opmuntre udvikling af biomedicinsk forskning, behandling og social støtte.

**Et anslået antal på 1.200.000 meget syge patienter i Europa venter på, at Parlamentet skal anerkende WHO ICD-10-koden G93.3 for ME**

**Dansk ME Forening** - Lajla Mark, formand

E-mail: [administration@dmeft.dk](mailto:administration@dmeft.dk) Web: [www.dmeft.dk](http://www.dmeft.dk)

## Referencer

1. [www.who.int/classifications/icf](http://www.who.int/classifications/icf)

G93.3 Postviral fatigue syndrome  
Benign myalgic encephalomyelitis (ME)
2. Carruthers B, Jain AK, De Meirleir KL, Peterson DL, Klimas NG, Lerner AM, Bested AC, Flor-Henry P, Joshi P, Powles AP, et al.: Myalgic encephalomyelitis/chronic fatigue syndrome: clinical working case definition, diagnostic and treatment protocols. *Journal of chronic fatigue syndrome* 2003, 11(1):7-115.
3. Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T et al. Myalgic encephalomyelitis: International Consensus Criteria. *J Intern Med* 2011;270:327-38.
4. Nacul LC, Lacerda EM, Campion P, Pheby D, Drachler MD, Leite JC, Poland F, Howe A, Fayyaz S, Molokhia M: The functional status and well being of people with myalgic encephalomyelitis/chronic fatigue syndrome and their carers. *BMC Public Health* 2011, 11(1):402.
5. J. Mark Van Ness, Staci R. Stevens, Kylie T. Kumasaka, Harnoor Singh, Betsy Keller, Daniel L. Peterson, Jose Montoya and Christopher R. Snell: A diagnostic test for the identification of metabolic dysfunction. *Conference abstract 9th IACFS/ME clinical and research conference, Reno, March 7, 2009.*
6. Brown, M. M., Bell, D. S., Jason, L. A., Christos, C. and Bell, D. E. (2012), Understanding Long-Term Outcomes of Chronic Fatigue Syndrome. *J. Clin. Psychol.*, 68: 1028–1035. doi: 10.1002/jclp.21880
7. Twisk, F.N., Maes, M., 2009. A review on cognitive behavioral therapy (CBT) and graded exercise therapy (GET) in myalgic encephalomyelitis (ME)/ chronic fatigue syndrome (CFS): CBT/GET is not only ineffective and not evidence-based, but also potentially harmful for many patients with ME/CFS. *Neuro Endocrinology Letters* 30 (3), 284–299.
8. KCE report: Evaluation of CBT/GET therapy.  
<https://kce.fgov.be/nl?SGREF=5268&CREF=11648>
9. Fluge Ø, Bruland O, Risa K, Storstein A, Kristoffersen EK, et al. (2011) Benefit from B-Lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. A Double-Blind and Placebo-Controlled Study. *PLoS ONE* 6(10): e26358. doi:10.1371/journal.pone.0026358
10. Maes M, Twisk FN: Chronic fatigue syndrome: Harvey and Wessely's (bio)psychosocial model versus a bio(psychosocial) model based on inflammatory and oxidative and nitrosative stress pathways. *BMC Med* 8:35.
11. Broderick G, Fuite J, Kreitz A, Vernon SD, Klimas N, Fletcher MA. A formal analysis of cytokine networks in chronic fatigue syndrome. *Brain Behav Immun.* 2010 Oct;24(7):1209-17.
12. Komaroff AL, Cho TA: Role of infection and neurologic dysfunction in chronic fatigue syndrome. *Seminars in Neurology* 2011, in press.

# European ME Alliance

European ME Alliance, Sønder Alle 5, st 3, 9500 Hobro, Denmark

Email: [info@euro-me.org](mailto:info@euro-me.org)

web: [www.euro-me.org](http://www.euro-me.org)

## For further information

1. Klimas NG, Salvato FR, Morgan R, Fletcher MA. Immunologic abnormalities in chronic fatigue syndrome. *J Clin Microbiol* 1990; 28: 1403-10. [PMID: 2166084]
2. Myhill S, Booth NE, McLaren-Howard J. Chronic fatigue syndrome and mitochondrial dysfunction. *Int J Clin Exp Med* 2009; 2: 1-16. [PMID: 19436827]
3. Peckerman, A., LaManca, J.J., Dahl, K.A., Chemitiganti, R., Qureishi, B., Natelson, B.H., 2003. Abnormal impedance cardiography predicts symptom severity in chronic fatigue syndrome. *American Journal of Medical Sciences* 326 (2), 55-60.
4. Streeten DH, Thomas D, Bell DS. The roles of orthostatic hypotension, orthostatic tachycardia and subnormal erythrocyte volume in the pathogenesis of the chronic fatigue syndrome. *Am J Med* 2000; 320: 1-8. [PMID: 10910366]
5. Kerr JR, Burke B, Petty R, et al. Seven genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis; a detailed analysis of gene network and clinical phenotypes. *J Clin Pathol* 2008; 61: 730-739. [PMID: 18057078]
6. Tirelli U, Chierichetti F, Tavio M, Simonelli C, Bianchin G, Zanco P, Ferlini G. Brain positron emission tomography (PET) in chronic fatigue syndrome: preliminary data. *Amer J Med* 1998; 105: 54S-8S. [PMID: 9790483]
7. Goldstein JA. Chronic Fatigue Syndrome: The Limbic Hypothesis. Binghamton, New York: Haworth Medical Press; 1993:19, 116.
8. Chia J, Chia A, Voeller M, Lee T, Chang R. Acute enterovirus infection followed by myalgic encephalomyelitis/chronic fatigue syndrome and viral persistence. *J Clin Pathol* 2010; 63: 163-8. [PMID: 19828908]
9. Pall ML. Explaining "Unexplained Illnesses": Disease Paradigm for Chronic Fatigue Syndrome, Multiple Chemical Sensitivity, Fibromyalgia, Post-Traumatic Stress Disorder, Gulf War Syndrome and Others. Binghamton, NY: Harrington Park (Haworth) Press, 2007.
10. Meeus M, Nijs J, McGregor N, Meeusen R, De Schutter G, Truijen S, Frémont M, Van Hoof E, De Meirlier K.: Unravelling intracellular immune dysfunctions in chronic fatigue syndrome: interactions between protein kinase R activity, RNase L cleavage and elastase activity, and their clinical relevance. In Vivo. 2008 Jan-Feb;22(1):115-21. PMID:18396793 [PubMed - indexed for MEDLINE] [Free Article](#)

For an objective view of the establishment intrigue surrounding ME we recommend:

**Magical Medicine: How to Make a Disease Disappear** by Professor Malcolm Hooper [  
[www.investinme.org/Article400%20Magical%20Medicine.htm](http://www.investinme.org/Article400%20Magical%20Medicine.htm)]

Professor Hooper has made a formal complaint to the Minister of State responsible for the Medical Research Council.